---
document_datetime: 2023-09-21 20:04:13
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/darzalex-epar-all-authorised-presentations_en.pdf
document_name: darzalex-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 1.49417
conversion_datetime: 2025-12-14 21:52:11.909145
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form                   | Route of Administration   | Immediate Packaging   | Content (concentration)   | Pack size                                                    |
|------------------|-------------------|------------|---------------------------------------|---------------------------|-----------------------|---------------------------|--------------------------------------------------------------|
| EU/1/16/1101/001 | Darzalex          | 20 mg/ml   | Concentrate for solution for infusion | Intravenous use           | vial (glass)          | 5 ml                      | 1 vial                                                       |
| EU/1/16/1101/002 | Darzalex          | 20 mg/ml   | Concentrate for solution for infusion | Intravenous use           | vial (glass)          | 20 ml                     | 1 vial                                                       |
| EU/1/16/1101/003 | Darzalex          | 20 mg/ml   | Concentrate for solution for infusion | Intravenous use           | Vial (glass)          | 5 ml + 20 ml              | Initiation pack: 11 vials (6 x 5 ml vials + 5 x 20 ml vials) |
| EU/1/16/1101/004 | Darzalex          | 1800 mg    | Solution for injection                | Subcutaneous use          | Vial (glass)          | 15 ml (120 mg/ml)         | 1 vial                                                       |